evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,721 questions · 19,640 findings · 2,039 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 3,754 · 19.1%GRADE not reported 1,273 · 6.5%Very low 4,859 · 24.7%Low 5,568 · 28.4%Moderate 3,240 · 16.5%High 946 · 4.8%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Immune‐enhancing supplements (oral or enteral) vs usual care or control

Non‐infectious complications · people undergoing gastrointestinal surgery

Immune‐enhancing supplements (oral or enteral) showed no clear difference in non‐ infectious complications recorded up to 30 days postdischarge compared with usual care or control (low certainty).

1 finding from 1 review

Summary of findings table ‐ Transcutaneous bilirubin (TcB) screening vs visual assessment

Readmission for phototherapy for hyperbilirubinemia · newborns for hyperbilirubinemia

Summary of findings table ‐ Transcutaneous bilirubin (TcB) screening probably leads to lower readmission for phototherapy for hyperbilirubinemia compared with visual assessment (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Transcutaneous bilirubin (TcB) screening vs visual assessment

Exchange transfusion · newborns for hyperbilirubinemia

Summary of findings table ‐ Transcutaneous bilirubin (TcB) screening showed no clear difference in exchange transfusion compared with visual assessment (low certainty).

1 finding from 1 review

Summary of findings table ‐ Transcutaneous bilirubin (TcB) screening vs visual assessment

Phototherapy before hospital discharge · newborns for hyperbilirubinemia

Summary of findings table ‐ Transcutaneous bilirubin (TcB) screening probably leads to higher phototherapy before hospital discharge compared with visual assessment (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Transcutaneous bilirubin (TcB) screening vs visual assessment

Acute bilirubin encephalopathy · newborns for hyperbilirubinemia

Summary of findings table ‐ Transcutaneous bilirubin (TcB) screening showed no clear difference in acute bilirubin encephalopathy compared with visual assessment (low certainty).

1 finding from 1 review

Intervention not reported

Pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…

The intervention may leads to lower pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512… (low certainty).

1 finding from 1 review

Intervention not reported

Mitoxantrone (Direct evidence; 1 RCT; 51 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…

The intervention may leads to lower mitoxantrone (Direct evidence; 1 RCT; 51 participants) (low certainty).

1 finding from 1 review

Intervention not reported

Natalizumab (Direct evidence; 1 RCT; 942 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…

The intervention leads to lower natalizumab (Direct evidence; 1 RCT; 942 participants) (high certainty).

1 finding from 1 review

Intervention not reported

Teriflunomide (Direct evidence; 1 RCT; 1169 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…

The intervention may leads to lower teriflunomide (Direct evidence; 1 RCT; 1169 participants) (low certainty).

1 finding from 1 review

Intervention not reported

Azathioprine (Direct evidence; 1 RCT; 59 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

It is very uncertain whether the intervention changes azathioprine (Direct evidence; 1 RCT; 59 participants) (very low certainty).

1 finding from 1 review

Intervention not reported

Cladribine (Direct evidence; 1 RCT; 1326 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

The intervention leads to lower cladribine (Direct evidence; 1 RCT; 1326 participants) (high certainty).

1 finding from 1 review

Intervention not reported

Dimethylfumarate (Direct evidence; 2 RCTs; 2307 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

The intervention probably leads to lower dimethylfumarate (Direct evidence; 2 RCTs; 2307 participants) (moderate certainty).

1 finding from 1 review

Intervention not reported

Azathioprine (Direct evidence; 1 RCT; 59 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…

It is very uncertain whether the intervention changes azathioprine (Direct evidence; 1 RCT; 59 participants) (very low certainty).

1 finding from 1 review

Intervention not reported

Fingolimod (Direct evidence; 2 RCTs; 2355 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

The intervention probably leads to lower fingolimod (Direct evidence; 2 RCTs; 2355 participants) (moderate certainty).

1 finding from 1 review

Intervention not reported

Glatiramer acetate (Direct evidence; 3 RCsT; 1014 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

The intervention probably leads to lower glatiramer acetate (Direct evidence; 3 RCsT; 1014 participants) (moderate certainty).

1 finding from 1 review